# Veterinary Compounding: Quality, Safety, and Clinical Decision-Making ## Key Takeaways - Compounded veterinary medications are prepared when approved commercial products are unavailable or cannot meet specific patient needs, but their use necessitates careful consideration of therapeutic necessity against documented risks of potency variation, contamination, and pharmacokinetic unpredictability. - Potency variability is a primary safety concern, as demonstrated by studies showing significant differences in drug content and clinical effect between compounded and FDA-approved formulations, such as with lomustine in canine cancer patients where neutropenia rates differed. - Compounding pharmacies must adhere to recognized quality standards, such as those set by the United States Pharmacopeial Convention (USP), which encompass facility, personnel, and documentation requirements, and veterinarians should verify a pharmacy's compliance. - Pharmacokinetic data for compounded products are limited and species-specific; extrapolation across species is not scientifically justified, and therapeutic drug monitoring or objective clinical assessment is crucial for drugs with narrow therapeutic indices. - Compounded intravenous fluids must meet stringent sterility and endotoxin standards, and the use of nonsterile water sources is unacceptable, highlighting the critical importance of microbiological quality for parenteral products. - Client communication is paramount, requiring informed consent that addresses potency uncertainty, lack of regulatory approval, and the necessity of specific monitoring plans to manage potential risks and benefits. --- Veterinary compounding is the preparation of customized medications to meet patient needs that approved commercial products cannot satisfy. This article provides a clinical reference for practicing veterinarians who prescribe compounded preparations, evaluate compounding pharmacy quality, and counsel clients on treatment options. It addresses the scientific basis for compounding decisions, regulatory frameworks that govern pharmacy practice, and the evidence available to guide clinical judgment across species. The decision to use a compounded medication requires weighing therapeutic necessity against documented risks of potency variation, contamination, and pharmacokinetic unpredictability. Published studies demonstrate that compounded products can differ substantially from FDA-approved formulations in both drug content and clinical effect. A comparative study of lomustine in dogs with cancer found that patients receiving a compounded formulation experienced significantly lower rates of neutropenia than those receiving the approved product, and subsequent potency testing of compounded lomustine capsules from five sources revealed marked variability in actual drug content. These findings illustrate why compounding decisions demand explicit consideration of the drug, the indication, the patient, and the pharmacy's quality systems. This article equips the reader to distinguish appropriate compounding scenarios from those where an approved product should be used, to evaluate a compounding pharmacy's compliance with recognized standards, and to communicate risk and benefit to owners in a balanced manner. It does not provide recipes or specific formulation guidance. ## At a Glance | Parameter | Clinical Consideration | |---|---| | Indication for compounding | Use when no approved product exists, when approved products are unavailable, or when a specific patient need cannot be met by an approved formulation | | Primary safety concern | Potency variability between compounded and approved products, documented for drugs such as lomustine | | Sterility requirement | Compounded intravenous fluids must meet sterility and endotoxin standards, nonsterile water sources are unacceptable | | Pharmacy quality standard | United States Pharmacopeia (USP) standards for compounding practice, including facility, personnel, and documentation requirements | | Species-specific caution | Pharmacokinetic data for compounded products are limited to specific drugs and species, extrapolation across species is not justified | | Antimicrobial stewardship | Compounded antimicrobials should not be used to circumvent approved products when an appropriate approved option exists | | Client communication | Owners should receive informed consent discussing potency uncertainty, lack of regulatory approval, and monitoring plans | ## The Regulatory Framework for Veterinary Compounding Compounding occupies a distinct position in drug regulation. The United States Food and Drug Administration (FDA) approves animal drugs for specific indications, species, and labeled conditions. Compounded preparations are not FDA-approved products, they are created by pharmacists or veterinarians to address individual patient needs. The FDA Center for Veterinary Medicine provides regulatory information on approved animal drugs, extralabel use, and compounding policy, and veterinarians should understand that compounding does not confer the same safety, efficacy, and quality assurances that accompany an approved product. The United States Pharmacopeial Convention, a nongovernmental standards-setting organization, develops standards for compounded preparations used in both human and veterinary health care. USP standards address formulation, compounding technique, facility requirements, and quality testing. A compounding pharmacy that claims USP compliance should be able to document adherence to these standards. For veterinary practitioners, verifying a pharmacy's USP compliance status is a reasonable first step in evaluating product quality, although compliance alone does not guarantee therapeutic equivalence to an approved drug. Regulatory requirements vary by jurisdiction. The World Organization for Animal Health publishes international standards for animal health and veterinary drug use, and practitioners outside the United States must consult their local regulatory authorities. Within the United States, state boards of pharmacy and the FDA share oversight of veterinary compounding, and the specific rules governing a prescription depend on whether the drug is a human-approved product compounded for veterinary use, a bulk drug substance, or an animal-approved product. ## Pharmacokinetic Considerations in Compounded Products Compounding alters drug delivery systems, excipients, and dosage forms, all of which can change absorption, distribution, metabolism, and elimination. The pharmacokinetic profile of a compounded product cannot be assumed to match that of the approved formulation. This principle is particularly important for drugs with narrow therapeutic indices or steep dose-response curves. A multidose pharmacokinetic study of a modified, compounded theophylline product in dogs provides a useful example. Theophylline is used in canine medicine for chronic bronchitis and bradyarrhythmias, yet no species-validated commercial products are available. In that study, eleven dogs received the compounded product at 10 mg/kg twice daily, and plasma concentrations remained between 5 and 30 μg/ml for 91 percent of the dosing interval. The study authors concluded that the regimen was safe and achieved appropriate plasma concentrations in most dogs. This work demonstrates that a well-characterized compounded product from a USP-compliant pharmacy can perform acceptably, but it also underscores that such data must be generated for each product instead of assumed. The absence of pharmacokinetic data for most compounded preparations creates genuine uncertainty. When a compounded product is used, the clinician should consider whether therapeutic drug monitoring is feasible, whether the drug has a wide safety margin, and whether clinical response can be assessed objectively. For drugs with narrow therapeutic windows, such as chemotherapeutic agents, the risks of potency variation are amplified. ## Quality Control and Product Integrity Compounded preparations vary in quality depending on the source, method of preparation, and adherence to standards. A prospective study comparing commercially available intravenous fluids to two forms of compounded isotonic crystalloid fluids for horses found that electrolyte concentrations were consistent within each product but differed between product types. More concerning, the hand-mixed method using chlorinated drinking water, a practice employed by some equine practitioners, was deemed unacceptable for intravenous administration. The study authors advised that equine practitioners obtain informed consent from owners when compounded fluids are used. This study highlights two distinct quality domains. First, chemical quality, meaning the concentration and identity of active ingredients and electrolytes, must match the intended formulation. Second, microbiological quality, meaning sterility and absence of endotoxin, is non-negotiable for parenteral products. A compounding pharmacy that prepares sterile products must maintain appropriate facilities, use sterile technique, and perform end-product testing where required. Veterinarians who compound in-clinic, particularly for intravenous use, must apply the same standards. For oral compounded products, potency testing is the primary quality concern. The lomustine study referenced earlier found that compounded capsules from five pharmacies varied in drug content, and this variability correlated with clinical outcomes. When a drug's efficacy depends on achieving a minimum systemic exposure, a subpotent product can lead to therapeutic failure, while a superpotent product can cause excessive toxicity. ## Clinical Scenarios Justifying Compounding Compounding is clinically appropriate in several defined circumstances. The most defensible indication is the absence of an approved product for the species or condition in question. Many drugs used in veterinary medicine are approved for humans only, and compounding allows access to these agents for animal patients. A second indication is the unavailability of an approved product due to manufacturing shortages or discontinuation. A third is the need for a specific dosage form, such as a flavored liquid for a cat that cannot swallow tablets, or a smaller capsule size for accurate dosing in a small dog. The use of compounded low-dose naltrexone in veterinary oncology illustrates a scenario where compounding enables a novel therapeutic approach. A case series of dogs with various cancers treated with oral low-dose naltrexone as part of palliative care reported improvements in quality of life domains including pain control, appetite, and mobility, with no adverse events. This report is hypothesis-generating instead of definitive, and the authors appropriately framed their findings as preliminary. The case series format cannot establish efficacy, and clinicians should interpret such evidence accordingly. Compounding is not appropriate when an approved product exists and can meet the patient's needs. Using a compounded product to reduce cost, to avoid a specific brand, or to circumvent regulatory requirements does not serve the patient's interest. This principle applies with particular force to antimicrobials. The American Veterinary Medical Association's antimicrobial stewardship guidance emphasizes judicious use of antimicrobials to preserve efficacy and limit resistance. Compounded antimicrobials should not be used when an approved product with appropriate spectrum, pharmacokinetics, and labeling is available. ## Species-Specific and Production-System Considerations Pharmacokinetic data generated in one species do not transfer reliably to another. A compounded product studied in dogs, such as the modified theophylline described above, cannot be assumed to behave identically in cats, horses, or exotic species. The clinician must consider species differences in drug metabolism, body size, and gastrointestinal physiology when prescribing a compounded preparation. Food-producing animals present additional concerns. Withdrawal times for compounded products are not established, and the absence of residue data creates risk for the food supply. Practitioners treating food animals must consult regulatory guidance on extralabel drug use and withdrawal interval estimation. The World Organization for Animal Health terrestrial animal health standards address veterinary drug use in the context of international trade, and practitioners should be aware that residues from compounded products can have trade implications. For companion animals, the primary considerations are efficacy, safety, and owner compliance. A compounded formulation that improves palatability and ensures the owner can administer the full course of therapy may be clinically superior to an approved product that the owner cannot give reliably. This practical benefit must be balanced against the quality uncertainties described throughout this article. ## Evaluating a Compounded Preparation Before Use The decision to use a compounded product should follow a structured assessment that weighs therapeutic necessity against product uncertainty. Begin by confirming that the prescribed drug is unavailable as an approved veterinary or human product in the required dosage form, strength, or combination. If an approved alternative exists, compounding is rarely justified unless the patient cannot tolerate the approved formulation. Next, evaluate the pharmacy itself. A compounding pharmacy should be able to document compliance with applicable compounding standards, including United States Pharmacopeia chapters relevant to nonsterile and sterile preparations. The [United States Pharmacopeial Convention develops standards and clinical information for compounded preparations used in veterinary medicine](https://pubmed.ncbi.nlm.nih.gov/23969515/), and a pharmacy that cannot articulate its quality processes should not receive the prescription. Request specific information from the pharmacy before dispensing: - Source and grade of active pharmaceutical ingredients - Beyond-use date and storage conditions - Potency and stability data for the specific formulation - Sterility and endotoxin testing results for sterile products - Batch records and release testing documentation - Adverse event reporting procedures For sterile compounded products, ask whether the pharmacy performs sterility testing on each batch and whether endotoxin testing is performed for fluids intended for intravenous administration. [Compounded crystalloid fluids prepared with nonsterile water sources have been shown to carry contamination risks that make them unsuitable for intravenous delivery in horses](https://pubmed.ncbi.nlm.nih.gov/29114956/), and similar scrutiny should apply to any sterile preparation. Document the evaluation in the medical record, including the reason for compounding, the pharmacy selected, the information obtained, and the client discussion regarding risks and benefits. ## Red Flags for Poor-Quality Compounding Products Several findings should raise immediate concern about a compounded preparation: - No beyond-use date or an extended beyond-use date unsupported by stability data - No lot number or batch identification - Inconsistent appearance, color, or texture between capsules or tablets from the same prescription - Pharmacy unable or unwilling to provide potency documentation - No sterility testing documentation for sterile products - Use of nonsterile water sources in intravenous fluids - Pricing substantially below the cost of the raw materials and quality testing - Pharmacy that does not require a valid veterinarian-client-patient relationship Potency failures are a documented concern. [Compounded lomustine capsules from multiple pharmacies showed variability in potency when tested by high-pressure liquid chromatography](https://pubmed.ncbi.nlm.nih.gov/26682700/), and the clinical consequences of underpotent chemotherapy are potentially severe. When a compounded product is used for a drug with a narrow therapeutic index, consider requesting potency verification from the pharmacy or an independent laboratory. ## Common Compounding Scenarios and Selection Criteria | Clinical Scenario | Compounding Justification | Preferred Approach | Monitoring | |---|---|---|---| | Chronic bronchitis in a dog requiring theophylline | No species-validated commercial product available | Use a USP-compliant pharmacy with published pharmacokinetic data for the formulation | Serum drug concentrations, clinical response, adverse effects | | Chemotherapy dose adjustment for small patients | Approved product strength exceeds prescribed dose | Compounded capsules from a pharmacy with potency documentation | Complete blood count at expected nadir, clinical status | | Flavoring to improve compliance in cats | Patient refuses approved formulation | Compounded oral suspension or flavored treat | Clinical response, observed administration | | Intravenous fluid therapy in horses during product shortage | Commercial fluids unavailable | Compounded fluids from a pharmacy with sterility and endotoxin testing | Electrolyte status, clinical signs of sepsis or phlebitis | | Palliative oncology support | Adjunctive therapy not available as approved product | Compounded low-dose naltrexone with structured quality-of-life assessment | Quality-of-life scores, adverse effects | The selection of a compounding pharmacy should be based on documented quality systems, not convenience or cost. For drugs with narrow therapeutic indices, request stability and potency data specific to the formulation being dispensed. For sterile products, require sterility and endotoxin documentation. ## Monitoring Parameters for Compounded Drug Therapy Monitoring requirements depend on the drug, the disease, and the route of administration. For orally administered compounded drugs, confirm that the patient is actually receiving the full dose. Compounded formulations may have palatability issues that lead to partial dosing, and the clinical response may reflect underdosing instead of drug failure. For drugs with measurable serum concentrations, such as theophylline, therapeutic drug monitoring is appropriate. [A modified compounded theophylline product administered twice daily achieved plasma concentrations between 5 and 30 μg/ml for most of the dosing interval in healthy dogs](https://pubmed.ncbi.nlm.nih.gov/34173985/), but individual patients vary. Measure serum concentrations after steady state is reached, typically after several days of dosing, and adjust based on the result and clinical response. For chemotherapy agents, monitor the expected toxicity profile. [Dogs receiving compounded lomustine showed a lower frequency of neutropenia than dogs receiving the FDA-approved formulation in one study](https://pubmed.ncbi.nlm.nih.gov/26682700/), a finding that may reflect reduced potency instead of improved tolerability. Neutropenia that is unexpectedly mild or absent should prompt concern about product potency, not celebration of tolerability. For sterile products administered intravenously, monitor for signs of contamination or pyrogenic reactions, including fever, tachycardia, hypotension, or injection site inflammation. Document any adverse events and report them through the appropriate pharmacovigilance channels. ## Documentation and Client Communication The medical record should include the rationale for compounding, the specific pharmacy used, the formulation prescribed, and the monitoring plan. If the pharmacy provided stability or potency documentation, note that in the record. If the client was informed about the differences between approved and compounded products, document that discussion. Client communication should address the practical realities of compounded products without overstating their equivalence to approved drugs. Explain that compounded products are not FDA-approved, that quality varies among pharmacies, and that the product may differ in potency, stability, and absorption from an approved formulation. For production animals, discuss withdrawal times and the absence of established withdrawal data for most compounded products, and consult [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) where international standards apply. ## Antimicrobial Stewardship and Compounding Compounding does not alter the principles of judicious antimicrobial use. A compounded antimicrobial should be prescribed only when an approved antimicrobial is genuinely unavailable or inappropriate, and the choice of agent should follow established stewardship guidelines. [Professional guidance on antimicrobial stewardship emphasizes selecting the correct drug, dose, and duration based on culture and susceptibility data where available](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance). Compounding an antimicrobial to create a fixed-dose combination or to extend an expiration date does not justify use that would otherwise be inappropriate. For food-producing animals, compounding antimicrobials raises additional concerns about withdrawal periods and residue avoidance. No compounding pharmacy can provide validated withdrawal intervals for a product that has not undergone the required residue studies. The prescribing veterinarian bears responsibility for ensuring that treated animals do not enter the food supply with violative residues. ## Recognized Complications and Failure Modes Compounded preparations fail along predictable pathways. Potency deviation is the most extensively documented. In one study, dogs receiving a compounded lomustine formulation developed neutropenia far less frequently than dogs given the FDA-approved product, and subsequent high-pressure liquid chromatography testing of 5 mg capsules from five compounding sources confirmed substantial potency variability ([Frequency and Severity of Neutropenia Associated with Food and Drug Administration Approved and Compounded Formulations of Lomustine in Dogs with Cancer](https://pubmed.ncbi.nlm.nih.gov/26682700/)). The clinical consequence of subpotent chemotherapy is also lack of effect, it is silent underdosing of a cytotoxic agent with a narrow therapeutic index. Sterility and contamination failures constitute a second major category. Compounded crystalloid fluids prepared with chlorinated drinking water for intravenous use in horses failed quality standards for sterility or endotoxin content, and the authors concluded this water source is unacceptable for compounding ([Quality Control of Compounded Crystalloid Fluids for Intravenous Delivery to Horses](https://pubmed.ncbi.nlm.nih.gov/29114956/)). This finding matters beyond equine practice because it illustrates that the raw material supply chain, also the compounding process, determines final product safety. Stability failures are less dramatic but more common. A compounded product that is chemically stable at release may degrade before the beyond-use date if the formulation, packaging, or storage conditions are inappropriate. Unlike potency failures, which are detected by therapeutic response or lack thereof, stability failures often present as unexplained treatment failure or unexpected toxicity after weeks of apparently adequate therapy. Early detection depends on vigilance instead of routine testing, since most practices cannot assay compounded products. Monitor therapeutic response against expected pharmacodynamics. For drugs with measurable endpoints, such as theophylline and its target plasma concentrations, consider therapeutic drug monitoring when response is inadequate ([Multidose pharmacokinetics and safety of a modified, compounded theophylline product in dogs](https://pubmed.ncbi.nlm.nih.gov/34173985/)). For antimicrobials, clinical resolution within the expected timeframe is the primary check. For chemotherapy, serial complete blood counts provide an objective, if indirect, measure of drug delivery. Document lot numbers, beyond-use dates, and pharmacy sources so that a suspected failure can be traced and reported. ## Common Clinical Errors and Corrective Actions The most frequent error is treating a compounded product as bioequivalent to the manufactured drug. Compounded formulations differ in excipients, particle size, salt form, and release characteriztics. A clinician who switches a patient from a sustained-release commercial product to a compounded immediate-release formulation without adjusting dosing interval invites toxicity or breakthrough symptoms. A second error is extrapolating human compounding data to veterinary patients. The pharmacokinetic behavior of a drug in a dog or horse cannot be assumed from human references. Species differences in metabolism, protein binding, and gastrointestinal physiology alter absorption and clearance. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) and species-specific pharmacokinetic studies should inform dose selection, not human formularies. A third error is failing to verify the pharmacy's capabilities before prescribing. Not all pharmacies that advertise veterinary compounding maintain the equipment, training, or quality systems for the dosage form requested. A pharmacy that produces acceptable oral capsules may lack the facilities for sterile ophthalmic preparations. Confirm the pharmacy's specific accreditation and its experience with the drug and dosage form in question. A fourth error is neglecting to reassess therapy. Compounded drugs are often initiated for a specific indication, but ongoing necessity is rarely revisited. Schedule a recheck that includes both clinical response and a decision point for continuation, dose adjustment, or discontinuation. ## Limitations of the Evidence Base Published data on veterinary compounded products are sparse and skewed toward case series and small pharmacokinetic studies. The low-dose naltrexone experience in canine oncology, for example, involved seven enrolled dogs with four evaluable, and while owners reported maintained or improved quality of life, the design cannot establish efficacy ([Case Series of Veterinary Cancer Patients Treated with Oral Low-Dose Naltrexone](https://pubmed.ncbi.nlm.nih.gov/41819128/)). Such reports generate hypotheses, they do not confirm them. Expert opinion diverges on several points. There is no consensus on acceptable potency limits for compounded veterinary products, on whether bioequivalence testing should be required before a compounded product substitutes for a manufactured drug, or on how aggressively to pursue therapeutic drug monitoring for narrow-index drugs. Some clinicians accept compounded products from any licensed pharmacy, others restrict prescribing to pharmacies with third-party certification. Both positions are defensible given the current evidence, but they produce different risk profiles. Regulatory standards continue to evolve, and the [United States Pharmacopeial Convention](https://pubmed.ncbi.nlm.nih.gov/23969515/) has been active in developing standards and clinical information for veterinary compounded preparations. Clinicians should track changes to these standards because they affect what a pharmacy must do to produce a given preparation. ## Escalation and Referral Triggers Referral or specialist consultation is warranted when a patient fails to respond to a compounded product at an appropriate dose, when therapeutic drug monitoring reveals subtherapeutic or supratherapeutic concentrations, or when an adverse event is suspected to result from a compounding error. Veterinary oncologists should be involved when compounded chemotherapy is considered, given the potency risks documented for these products. Clinical pharmacologists or veterinary teaching hospitals can assist with pharmacokinetic assessment and alternative formulation strategies. Laboratory involvement is appropriate when contamination is suspected. A product that causes pyrexia, bacteremia, or local infection after administration should be retained and submitted for sterility and endotoxin testing. The [FDA Center for Veterinary Medicine](https://www.fda.gov/animal-veterinary) accepts adverse event reports and investigates compounding-related concerns. Regulatory reporting is mandatory in specific circumstances: suspected product contamination, significant potency deviation, or adverse events attributable to a compounded preparation. Reporting protects other patients and supports the regulatory oversight that underpins compounding quality. When in doubt about whether an event is reportable, contact the relevant authority and describe the circumstances. | Observation | Likely Cause | Discriminating Check | |---|---|---| | No therapeutic response at expected dose | Subpotent product, poor bioavailability, or incorrect diagnosis | Verify pharmacy assay data, consider therapeutic drug monitoring, reassess diagnosis | | Toxicity at standard dose | Superpotent product, altered release kinetics, or drug interaction | Review concurrent medications, assay product if retained, reduce dose and monitor | | Fever or injection-site reaction after parenteral administration | Contamination or endotoxin | Retain product, request sterility and endotoxin testing, report to regulatory authority | | Variable response between refills | Batch-to-batch inconsistency | Compare lot numbers, request certificate of analysis for each batch | | Clinical response but unexpected laboratory abnormalities | Excipient-related effect or stability degradation | Review formulation components, check beyond-use date, consider alternative pharmacy | ## Frequently Asked Questions ### How Do I Document Compounding Decisions in the Medical Record? Document the medical rationale for selecting a compounded preparation over an approved product, including the specific patient factors that preclude use of the commercial formulation. Record the active ingredient, strength, dosage form, prescribed dose, administration route, and the name and location of the compounding pharmacy. Note the expected duration of therapy and the monitoring plan. Include the client communication summary, particularly any discussion of potency variability, stability limitations, and the informed consent conversation. For food-producing animals, document withdrawal interval determination and the basis for that calculation. The [FDA Center for Veterinary Medicine](https://www.fda.gov/animal-veterinary) provides guidance on record requirements for extralabel drug use that applies to compounded preparations. ### What Should I Do When a Compounding Pharmacy Cannot Provide Stability Data? Request the pharmacy's stability documentation in writing before dispensing. If the pharmacy cannot supply data from a recognized reference, such as the United States Pharmacopeia, or from its own batch testing, treat the product as having unknown stability. Choose a shorter beyond-use date than the pharmacy suggests, typically no longer than the manufacturer's published data support. Consider whether an alternative dosage form or a different pharmacy can provide better documentation. For critical medications, such as antimicrobials or chemotherapeutics, verify potency concerns directly with the pharmacist. The [USP standards for compounded preparations](https://pubmed.ncbi.nlm.nih.gov/23969515/) describe the expected quality framework, and products falling outside that framework warrant additional caution. ### How Do I Manage Cost Constraints Without Compromising Patient Safety? When cost limits the treatment options, first determine whether an FDA-approved product can be used at a reduced frequency or alternative dose. If compounding remains necessary, compare pricing across several pharmacies, but do not select solely on cost. Request certificates of analysis for potency and sterility from any pharmacy under consideration. For expensive drugs such as lomustine, potency variability between pharmacies has been documented, and neutropenia frequency differs between approved and compounded formulations in dogs. Discuss the cost difference transparently with the client, and explain what additional quality assurance the higher-priced pharmacy provides. If the client cannot afford the higher-quality source, document that discussion and consider whether the drug is essential or whether a therapeutic alternative exists. ### How Do I Approach Compounded Fluids for Equine Patients When Commercial Products Are Unavailable? Commercial isotonic fluids remain the preferred choice for intravenous administration in horses. When shortages force the use of compounded fluids, verify the source of water used in preparation. Chlorinated drinking water is not acceptable for compounding intravenous crystalloids because of contamination risks. Confirm that the compounding pharmacy follows sterile compounding standards and can provide endotoxin and sterility testing results. Inspect the final product for particulate matter, turbidity, and correct volume before administration. Use in-line filtration during delivery where feasible. Obtain informed consent from the owner that acknowledges the increased risk associated with compounded fluids compared with approved commercial products. ### What Monitoring Is Required When Switching a Patient from an Approved Drug to a Compounded Version? Establish a baseline assessment before the switch, including the clinical sign being treated and any relevant laboratory values. Schedule a recheck at a time point consistent with the drug's expected onset of action and the condition being managed. For drugs with narrow therapeutic windows, such as theophylline in dogs, consider measuring serum drug concentrations after steady state is reached. Monitor for both therapeutic failure and unexpected adverse effects, since potency differences can produce either subtherapeutic exposure or toxicity. Document the response in the medical record and compare it with the patient's historical response to the approved product. If the response differs, request potency analysis from the pharmacy and consider returning to the approved formulation. ### How Should I Explain Compounding Risks to a Client Who Requests a Specific Formulation? Explain that compounded drugs are not FDA-approved and therefore have not undergone the same quality and efficacy review as commercial products. Describe the potential for potency variation between batches and between pharmacies, and mention that clinical response may differ from the approved product. Use concrete examples from the veterinary literature, such as documented differences in neutropenia rates between approved and compounded lomustine in dogs. Explain the reasons compounding may still be appropriate, including dosage form flexibility and drug availability. Provide the client with the pharmacy name and contact information, and encourage them to report any unexpected effects promptly. The [AVMA practice resources](https://www.avma.org/resources-tools) offer client communication materials on medication safety that can support this conversation. ## Related Clinical & Scientific Guides * [Veterinary Formulary Essentials: Navigating Drug References](/knowledge/veterinary-medicine/clinical-pharmacology/veterinary-formulary-essentials-navigating-drug-references) * [Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-antiepileptic-veterinary) * [Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-corticosteroids-veterinary-comprehensive) ## References and Further Reading - [Heartworm-, Flea-, and Tick-associated Diseases in Dogs: A Review of Common Parasites and Drug Classes Prophylactic Against Them.](https://pubmed.ncbi.nlm.nih.gov/38768500/). 2024. - [Multidose pharmacokinetics and safety of a modified, compounded theophylline product in dogs.](https://pubmed.ncbi.nlm.nih.gov/34173985/). 2021. - [Quality Control of Compounded Crystalloid Fluids for Intravenous Delivery to Horses.](https://pubmed.ncbi.nlm.nih.gov/29114956/). 2018. - [United States pharmacopeia convention standards and clinical information for compounded medications used in veterinary medicine.](https://pubmed.ncbi.nlm.nih.gov/23969515/). 2007. - [Frequency and Severity of Neutropenia Associated with Food and Drug Administration Approved and Compounded Formulations of Lomustine in Dogs with Cancer.](https://pubmed.ncbi.nlm.nih.gov/26682700/). 2016. - [Case Series of Veterinary Cancer Patients Treated with Oral Low-Dose Naltrexone.](https://pubmed.ncbi.nlm.nih.gov/41819128/). 2026. - [FDA Center for Veterinary Medicine: Animal Drug Information](https://www.fda.gov/animal-veterinary). FDA CVM. - [AVMA Antimicrobial Use and Stewardship](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance). American Veterinary Medical Association. - [MSD Veterinary Manual, Professional Edition](https://www.msdvetmanual.com/). MSD Veterinary Manual. ## Related Articles - [Drug Interactions in Polypharmacy: A Clinical Decision Framework](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-polypharmacy-clinical-decision-framework) - [Chemotherapy Safety Protocols for Veterinary Oncology Nursing](/knowledge/veterinary-medicine/clinical-pharmacology/chemotherapy-safety-protocols-veterinary-oncology-nursing) - [Pharmacokinetics in Veterinary Patients: Clinical Application of Drug Disposition](/knowledge/veterinary-medicine/clinical-pharmacology/pharmacokinetics-veterinary-patients-clinical-application-drug-disposition) - [Drug Interactions with Antiemetics in Veterinary Patients: Clinical Considerations](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-antiemetics-veterinary-patients) - [Drug Interactions with Opioid Analgesics in Veterinary Patients: Clinical Implications](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-opioid-analgesics-veterinary) > This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.